Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $29.5300 (-0.77%) ($26.1200 - $30.4000) on Fri. May. 4, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.22% (three month average) | RSI | 91 | Latest Price | $29.5300(-0.77%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 6.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(23%) IBB(21%) XOP(18%) IWO(17%) QQQ(17%) | Factors Impacting ADMS price | ADMS will decline at least -2.11% in a week (0% probabilities). VIXM(-11%) UNG(-10%) BNDX(-9%) UUP(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.11% (StdDev 4.22%) | Hourly BBV | 0 () | Intraday Trend | -2.9% | | | |
|
5 Day Moving Average | $29.85(-1.07%) | 10 Day Moving Average | $29.39(0.48%) | 20 Day Moving Average | $27.38(7.85%) | To recent high | -19.3% | To recent low | 30.6% | Market Cap | $835m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |